Free Trial
→ The trade I’ve been waiting for since 2011 (From Traders Agency) (Ad)tc pixel
OTCMKTS:BAYRY

Bayer Aktiengesellschaft Earnings Date & Estimates

Bayer Aktiengesellschaft logo
$12.24 +0.17 (+1.41%)
As of 10/9/2026 03:59 PM Eastern

Bayer Aktiengesellschaft is expected to report earnings on Tuesday, November 3, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is expected to post earnings of $0.13 per share on revenue of $11.32 billion. Bayer Aktiengesellschaft last reported on August 4, 2026, posting $0.29 per share and beating the $0.23 consensus estimate. Bayer Aktiengesellschaft has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.13
Expected Revenue
$11.32 billion

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.29 (Beat by +$0.06)
Last Quarter Revenue
$12.53 billion
EPS Beat Rate
5 of last 8 quarters

Prepare for the Earnings Call

Bayer Aktiengesellschaft Earnings FAQ

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is estimated to report earnings on Tuesday, November 3, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Bayer Aktiengesellschaft to post earnings of $0.13 per share for the quarter.

The consensus revenue estimate for Bayer Aktiengesellschaft is $11.32 billion for the quarter.

Bayer Aktiengesellschaft Earnings Headlines

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
October 8 at 4:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261007322202/en/Bayer-to-Present-New-Cardiac-Amyloidosis-and-Heart-Failure-Data-at-the-Heart-Failure-Society-of-America-HFSA-Annual-Scientific-Meeting/
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
October 8 at 2:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261007583229/en/u.s.-fda-accepts-bayer%e2%80%99s-supplemental-new-drug-application-for-kerendia%c2%ae-finerenone-to-treat-adults-with-chronic-kidney-disease-ckd-without-diabetes/
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
Bayer’s Real‑World Prostate Cancer Study Signals Key Trends for Treatment Adoption in Canada
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bayers-realworld-prostate-cancer-study-signals-key-trends-for-treatment-adoption-in-canada?utm_source=marketbeat.com&utm_medium=referral
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
October 2, 2026  |  wsj.comhttps://www.wsj.com/health/pharma/bayer-to-invest-2-2-billion-in-u-s-pharma-manufacturing-expansion-ec038b86
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
October 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261002202241/en/bayer-to-invest-2.2-billion-u.s.-dollars-in-a-new-manufacturing-site-in-the-united-states/
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is a Germany-based life science company focused on health care and agriculture. Through its Pharmaceuticals, Consumer Health and Crop Science businesses, the company develops and markets products intended to improve human health, everyday self-care and agricultural productivity.

Bayer’s Pharmaceuticals business provides prescription medicines in areas such as cardiovascular disease, women’s health, oncology and specialty medicine. Its Consumer Health division offers nonprescription products in categories including pain relief, nutritional supplements, dermatology and allergy care, with brands such as Aspirin and Claritin. The Crop Science business supplies seeds, crop protection products and digital agricultural solutions for farmers and other agricultural customers.

Founded in 1863, Bayer is headquartered in Leverkusen, Germany, and serves customers in markets around the world. The company expanded its agricultural operations through the acquisition of Monsanto in 2018, adding seed and crop protection businesses to its portfolio. Bayer is led by Chief Executive Officer Bill Anderson, who assumed the role in June 2023.

View Bayer Aktiengesellschaft Profile
Earnings Tools